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(by R$1,011) and effectiveness (by 2.7%) were greater compared to VAN, resulting in 
an ICER of R$37,564 per successfully treated patients. But compared to TEI, LZD had 
lower costs (by R$2,246) and greater effectiveness (by 13.3%), with LZD being the 
‘dominating’ treatment. Majority of treatment costs were related to hospital stay, 
primarily ICU (73% in private and 50% in public scenario). Several scenarios were 
tested by varying treatment duration (7or14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). Results for all scenarios were similar to the base 
case from public and private perspectives. CONCLUSIONS: From private perspective 
LZD is a cost-effective alternative to VAN and TEI for treatment of MRSA-confirmed 
NP, owing primarily to its higher clinical response rate. From public perspective, LZD 
can be considered cost effective since its ICER vs. VAN is within 2-3 times Brazil’s 
GDP per capita.
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OBJECTIVES: The objective of the review was to determine the most widely used 
estimates of United States (US) costs of different stages of liver disease in patients 
with hepatitis C virus (HCV) in cost-effectiveness analyses (CEA). METHODS: A 
systematic literature search using predetermined search terms was performed 
to identify English-language articles that report cost or CEA from 1995 to 2014. 
Full texts were obtained and reviewed to determine study eligibility on the basis 
of predefined inclusion and exclusion criteria. All costs were inflated to 2014 
values. RESULTS: A total of 53 articles were eligible for review. In primary cost 
studies, two methods were generally used to derive the disease state costs: 
microcosting using treatment algorithms and unit costs; or statistical analyses 
of observational databases. The most widely used primary cost estimates in CEAs 
completed before 2011 were those derived using treatment algorithms by Bennett 
and colleagues (1997). A CEA published in 2012 by Gellad and colleagues presented 
updated resource use and costs for all the disease stages based on the Bennett 
study and added mild/moderate chronic HCV, compensated cirrhosis, and post-
SVR health states. The most widely used primary cost estimates in CEAs completed 
after 2012 are those obtained from a large database study by McAdam-Marx and 
colleagues (2011). This study provides estimates for all liver stages but does not 
include subcategories for decompensated disease. The estimates from the dif-
ferent sources were quite different; for example, for cirrhosis and hepatocellular 
carcinoma Gellad estimated $745 and $45,728 per year while McAdam-Marx esti-
mated $2,584 and $50,658 per year, respectively. CONCLUSIONS: There are many 
estimates of costs of HCV liver disease and these estimates can vary widely due 
to differences in study methodology. Understanding the differences in these esti-
mates can aid in the selection of the most appropriate inputs for use in economic 
models.
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OBJECTIVES: AASLD/IDSA have recently updated their treatment guidelines to 
include sofosbuvir-based therapy as recommended regimen for treatment-naïve and 
previously treated patients with hepatitis C (HCV) genotype 1 infection. The purpose 
of the study was to compare the cost-effectiveness of sofosbuvir-based combination 
therapies vs. peg-IFN and ribavirin (PEGIFN) among treatment-naïve patients and 
compare sofosbuvir-based combinations with and without interferon among patients 
previously treated with PEGIFN. METHODS: Cost per sustained viral response (SVR) 
was performed using a decision tree. It was assumed that patients were equally likely 
to receive either treatment. The model contained clinical data from Phase III clinical 
trials for PEGIFN (T1), sofosbuvir triple therapy (T2) (NEUTRINO study), and sofos-
buvir plus simeprevir and/or ribavirin (T3) (COSMOS study); drug and medical costs 
were obtained from the National Average Drug Acquisition Costs Database (Medicaid) 
and literature. Time horizon was 48 weeks for both analyses. RESULTS: Average cost 
among the treatment-naïve was $79,749 for T1 arm (52% SVR), $101,317 for T2 (91% 
SVR), and $147,386 for T3 (94% SVR). Among the pre-treated, the average cost was 
$142,862 for T2 (72% SVR) and $187,664 for T3 (94% SVR). Among the treatment-naïve, 
an ICER of $553 and $719 per 1%SVR gain was obtained for T2 vs. T1 and T3 vs. T1, 
respectively. Among the pre-treated, an ICER of $2036 per 1%SVR was obtained for T3 
vs. T2. In sensitivity analysis, no other factor but %SVR impacted incremental costs 
per responder. CONCLUSIONS: Although sofosbuvir-based combination without 
interferon was found to be the most expensive treatment it achieved the highest 
SVR rates among treatment-naive and pre-treated patients. The presented results 
can be used to make decisions by individual payers’ based on their willingness to pay 
thresholds. Future studies should examine the cost-effectiveness of new therapies 
by relevant HCV patient subgroups.
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OBJECTIVES: A 2010 randomized controlled trial, the first in the United States (US), 
was carried out to study the clinical effectiveness of pre-exposure HIV prophylaxis 
(PrEP) among men-who-have-sex-with-men (MSM) population over a follow up of 
diagnosis and treatment of hospitalized patients with infections carries a significant 
cost and suggests potential benefits in reducing time to diagnosis.
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OBJECTIVES: Malaria treatment in health care facility represents a standard prac-
tice in malaria case management. The study estimated the costs of treatment for 
uncomplicated malaria from a healthcare facility, to generate current information 
for appropriate decision making in resource or funding allocations for malaria 
treatment and control in Nigeria. METHODS: Based on a comprehensive cost of 
illness approach, hospital associated costs of uncomplicated malaria episodes 
were estimated from a provider perspective, applying a standard costing procedure 
for outpatient services. Capital and recurrent expenditures were estimated using 
ingredient approach combined with step-down methodology to calculate the final 
costs. Costs attributable to malaria treatment were calculated based on the propor-
tion of uncomplicated malaria cases treated within in the period. Non-hospital 
costs were not collected. Total and average financial and economic costs were 
estimated for uncomplicated malaria. All costs were calculated in local currency, 
converted to the US Dollars at the 2013 exchange rate. RESULTS: The hospital 
spent a total annual economic cost of N31.612 million (US$201,352.30) for the treat-
ment of uncomplicated malaria, at US$34.66 per case. This represents about 20% of 
the hospital total expenditure within the year. Personnel accounted for over 81% of 
the expenditure as the dominant cost driver, followed by antimalarial drugs, 7.8%. 
Over 45% of outpatients visits were treated for malaria in the facility, leading to 
increased utilization of hospital resources. Changes in personnel costs, drug prices 
and malaria prevalence significantly impacted on the study results, indicating the 
need for improved efficiency in the hospital resource utilization. CONCLUSIONS: 
Malaria treatment at the medical center constitutes a considerable amount of 
hospital expenditure, arising mainly from the cost of personnel and high propor-
tion of malaria treatment. For a more effective healthcare system, there is need 
for more efficient use of hospital resources to prevent wastages and reduce costs 
to the provider and consumer.
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OBJECTIVES: This study sought to estimate the average outpatient cost of providing 
adult antiretroviral therapy (ART) at an urban care centre for the ﬁrst year following 
ART initiation. METHODS: A retrospective, ingredients-based costing approach was 
implemented, as previously described in literature. Medical records for a conveni-
ent sample of 120 patients were reviewed 1 year after ART initiation. Subjects were 
assigned to any one of the following outcome categories based on their status at 
the end of the study period: in care and responding (IC); in care but not responding 
(NR); or no longer in care at study site (NIC). Average cost per outcome category 
was estimated based on resource utilisation, in 2013 US$. RESULTS: The overall 
annual retention in care was 93.3%. At the end of the first 12 months of ART care, 
109 (90.8%) of the patients were IC, 7 (6.7%) patients were NIC and 3 (2.5%) patients 
were NR. The average outpatient cost per patient initiated was USD $461. The costs 
were structured as follows; outpatient visits (49.2%), medications (26.4%), laboratory 
tests (21.8%) and fixed costs (2.6%). The average cost to produce an IC patient was 
US$ 472, NR US$ 438 and NIC US$ 322. The average cost of producing a patient in 
care and responding to ART represented 49.2% of the country’s GDP per capita for 
2013. This estimate excludes building and utility costs because they were unavail-
able, hence the actual average cost may be higher. CONCLUSIONS: These findings 
show that maintaining an HIV/AIDS patient in care and responding to ART is an 
expensive undertaking relative to the country’s GDP per capita. This underscores 
the need for periodic costing studies as a way of continually monitoring the costs 
and cost structures associated with caring for people living with HIV and AIDS, as 
this would aid in planning and decision-making.
PIN49
aN ecoNomIc modeL to comPare LINeZoLId, vaNcomycIN, aNd 
teIcoPLaNIN for the treatmeNt of coNfIrmed methIcILLIN-reSIStaNt 
StaPhyLococcuS aureuS NoSocomIaL PNeumoNIa IN braZIL
Niederman M.S.1, Patel D.2, Li J.Z.3, Charbonneau C4, Ferreira C.N.5, Figueiredo L.5, Stephens 
J.M.2, Haider S.6
1Winthrop-University Hospital, Mineola, NY, USA, 2Pharmerit International, Bethesda, MD, USA, 
3Pfizer, Inc., San Diego, CA, USA, 4Pfizer Inc, Paris, France, 5Pfizer Brasil, São Paulo, Brazil, 6Pfizer 
Inc, Groton, CT, USA
OBJECTIVES: To evaluate economic impact of linezolid (LZD) versus vancomy-
cin (VAN) and teicoplanin (TEI) for treatment of confirmed methicillin-resistant 
Staphylococcus aureus (MRSA) nosocomial pneumonia (NP) in Brazilian private 
and public healthcare systems. METHODS: A 4 week decision model was developed 
capturing 1st and 2nd line therapy. Published literature, local sources, and expert 
opinion provided clinical and resource use data, such as efficacy, mortality, adverse 
events (AEs), treatment duration, and length of hospital/ICU stay. Brazil cost data 
was obtained from local published sources and micro-costing. Base-case analysis 
used 14-day treatment duration. In event of treatment failure/severe AEs on 1st-line 
therapy, drug was switched after 7 days. Costs were reported in 2014 Brazilian Real. 
Scenario based sensitivity analyses were conducted. RESULTS: From private per-
spective, LZD was associated with lower costs (by R$5,760 and R$10,551), and greater 
overall treatment success (by 2.7% and 13.3%) compared to VAN and TEI respectively, 
resulting in LZD ‘dominating’ both treatments. From public perspective, LZD costs 
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OBJECTIVES: To examine the clinical and economic impact of diagnostic-driven 
(DD) versus empiric treatment strategies in neutropenic patients with suspected 
Aspergillus invasive fungal infections (IFIs) in Beijing, Chengdu, and Guangzhou, 
China. METHODS: A decision-analytic model was used to estimate total costs 
and survival associated with a DD and empiric treatment strategy for managing 
suspected IFIs in adult patients with neutropenia due to hematological malig-
nancy or autologous/allogeneic stem cell transplant. In the DD strategy, IFI was 
identified via serum galactomannan (GM) enzyme-linked immunosorbent assay 
(ELISA) so that early initiation of targeted treatment could be administered. IFI 
incidence (10.9%), portion of actual IFIs diagnosed via empiric treatment (30%), 
overall mortality (10.7%), and IFI-related mortality (28.6%) were obtained from 
the literature. Survival rates were generated based on the proportion of patients 
with identified and appropriately treated IFIs. Empiric and DD treatment pat-
terns and resource use were based on clinical opinion (3-5 clinicians from top 
hospitals per city). Medical costs (in 2014 Chinese Yuan [¥]) included antifungal 
drugs, treatment-related adverse events, and other medical resource costs. City-
specific costing sources were used wherever possible. RESULTS: Medical costs 
were lower for the DD versus the empiric strategy in Beijing (¥4,118 vs ¥5,245), 
Chengdu, (¥5,463 vs ¥6,389), and Guangzhou (¥9,762 vs ¥10,351). Fewer patients 
received antifungal treatment using the DD strategy (6.7% versus 11.4%), and sur-
vival rates were similar. One-way sensitivity analysis showed results were most 
sensitive to changes in GM test sensitivity followed by IFI incidence. Probabilistic 
sensitivity analysis showed that treating via a DD strategy was dominant 99% of 
the time. CONCLUSIONS: These results suggest that in China, a DD strategy to 
identify IFIs in immunocompromised patients with persistent fever in order to 
better target antifungal treatment compared to an empiric antifungal treatment 
strategy may be cost-saving, while maintaining a similar overall survival rate.
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OBJECTIVES: We aimed to assess cost-effectiveness of ceftaroline fosamil (CF) for 
treatment of hospitalised patients with pneumococcal community-acquired pneu-
monia (PCAP) in Russia from societal perspective. METHODS: Decision tree model 
based on results of two 3rd phase clinical trials (FOCUS1/FOCUS2) was created to 
assess clinico-economic implications of PCAP treatment with CF vs. ceftriaxone 
(CS) for society. Day 4 early clinical response (73% vs. 56%, p= 0,03) was taken for 
effectiveness outcome. Direct and indirect expenses associated with initial episode, 
possible recurrence of PCAP, direct and delayed attributive mortality were taken into 
consideration. Original drugs costs were extracted from wholesale prices database 
(www.pharmindex.ru). Cost of therapy was calculated to correspond treatment regi-
ments in selected trials: CF 600mg BID vs. CS 1g QD and common in Russia CS 2g 
QD. Alternative treatment in case of inefficacy was chosen per experts’ opinion. 
Indirect expenses evaluation was based on human capital approach (loss in GDP per 
capita) with 5% discount rate per year. All expenses were converted to US dollars at 
exchange rate on the date of calculation (June 2014). Uncertainty was explored in 
a series of one- and two-way deterministic and in probabilistic sensitivity analy-
sis. RESULTS: Respective total expenses of PCAP treatment with CF 600mg BID vs. 
CS 1g vs. CS 2g QD were as follows: $16548.6 vs. $16894.4 vs. $16972.3, making CF 
strategy the dominating one. Results were sensitive to change in rate of early clini-
cal response to comparators and duration of CF course. Given willingness-to-pay 
$12.8 per additional 1% of clinical response (per experts’ opinion) 95.1% and 97.3% 
of iterations in probabilistic sensitivity analysis recommended CF over CS 1g or 
2g QD for treatment of PCAP. CONCLUSIONS: CF 600mg BID is more cost effective 
then CS 1g or 2g QD in the treatment of hospitalised patients with PCAP in Russia 
from societal perspective.
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OBJECTIVES: CVC insertion is one of the most commonly performed medical pro-
cedures in the intensive care hospital setting. The clinical impact of SBT in the 
procedure has been demonstrated previously. However, little is known about the 
economic impact of such educational interventions. This study aimed to analyze 
the costs associated with outcomes attributable to the implementation of a SBT 
program for CVC insertion. METHODS: The SBT training interventions were imple-
mented for residents working in the MICU at OSF St. Francis Medical Center in 
Peoria, Illinois, from 09/01/2012 to 12/31/2013. Data from an historical control group 
(traditional training) was selected during a parallel time period from 09/01/2010 to 
12/31/2011. Collected information included total hospital cost, training cost, LOS, 
complications, and patient demographics. Costs were adjusted to 2014 dollars. 
Adjusted generalized linear models were used to estimate the margin effects for the 
cost and the effectiveness. RESULTS: 86 residents placed 353 CVC lines in patients 
three years (iPREX trial). The study objective was to estimate the cost-effectiveness 
of PrEP (Emtricitabine-Tenofovir combination pill) from the US payer perspective 
using both short-run and long-run outcomes. METHODS: We designed a decision 
analytical model using Excel® 2013 that mimicked the iPREX trial environment 
to compare costs and outcomes of PrEP plus usual care versus usual care alone 
(i.e. condom use). Outcomes included HIV cases averted over the trial period of 
3 years and life years gained (LYG) over a lifetime time horizon. Since the adher-
ence of PrEP was an important outcome measure in the trial, we factored in the 
PrEP adherence relationship of HIV acquisition into the model. Condom effective-
ness was defined as probability of remaining HIV negative, assuming consistent 
condom usage. All costs were adjusted to 2014. RESULTS: From our base-case 
analysis, the treatment arm (PrEP plus usual care) resulted in an incremental cost 
of $ 1,369,784 per HIV case averted over a 3-year time frame and an incremental 
cost of $ 34,973.50 per LYG over a lifetime time horizon. Our one-way sensitiv-
ity analysis suggested that condom effectiveness below 92% can make PrEP to 
be cost-saving per LYG. Our probabilistic sensitivity analysis suggested that the 
cost-effectiveness probability of PrEP is at least 50% if the payer is willing to pay 
a minimum of $45,000-$50,000 per LYG. CONCLUSIONS: The short-run value of 
PrEP from the US payer perspective may be greater than their willingness-to-
pay. Further research is warranted to understand subgroups where PrEP value 
differs as well as payers’ willingness-to-pay for HIV-specific and generic health 
outcomes.
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OBJECTIVES: An estimated 35 million people were living with HIV around the 
world in 2012. Although a toolbox of prevention methods including condoms, 
risk reduction counseling, voluntary circumcision, pre-exposure prophylaxis, and 
more are available, the development of an HIV vaccine is seen as the only hope 
for completely eradicating HIV. METHODS: A cost-effectiveness analysis of a par-
tially effective HIV vaccine in combination with pre-exposure prophylaxis (PrEP) 
for high risk people was performed from the perspective of a United States (US) 
healthcare payer using a patient’s lifetime horizon. Total direct costs, infections 
averted, and quality-adjusted life years (QALY) were the study outcomes. A deci-
sion tree modeled four preventive treatment strategies for high-risk men who have 
sex with men (MSM) in San Francisco: 1) vaccine and PrEP, 2) vaccine alone, 3) PrEP 
alone, and 4) no prevention strategy. RESULTS: A vaccine was found to be most 
cost-effective and dominant prevention strategy in this analysis. The incremental 
cost-effectiveness ratio (ICER) for a vaccine and PrEP combined was $45,704 per 
QALY, falling below a $100,000 per QALY willingness-to-pay threshold. An HIV vac-
cine alone was estimated to cost the payer $6,659 per infection averted and was a 
dominant strategy compared to no preventive intervention. PrEP alone cost more 
than $1.15 million at current pricing per infection averted, and combined with a 
vaccine, the cost per infection averted was reduced to $904,326. CONCLUSIONS: 
HIV incidence was the largest factor driving the cost per infection averted and 
cost per QALY for all prevention strategies, followed by the cost of PrEP for the 
two strategies that included it. US payers should actively advocate development, 
approval, coverage, and use of a vaccine to avert new HIV infections as a more 
cost-effective strategy than current preventive methods for people at high risk of 
HIV infection in the United States.
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OBJECTIVES: We assess the tradeoffs between the costs and benefits of choosing 
alternate HIV prevention strategies, including the status-quo (current HIV testing 
with antiretroviral therapy [ART] initiation at CD4 ≤ 500), testing (expanded HIV 
testing with ART initiation at CD4 ≤ 500), test-and-treat (expanded HIV testing 
and early ART start), and PrEP (PrEP initiation by uninfected individuals) strate-
gies. METHODS: A mathematical epidemiological model is developed to simulate 
HIV incidence among 15-65 year old MSM in LAC. An economic model uses the 
epidemic model results to estimate the cost and effectiveness of 624 variants of 
the testing, test-and-treat and PrEP strategies from a societal perspective. For 
each strategy, we estimate the number of new HIV infections averted, the dis-
counted costs and quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratios. The sensitivity and robustness of the estimates are assessed 
via univariate and bootstrapping probabilistic sensitivity analyses. RESULTS: In 
the base case analysis, test-and-treat, PrEP, and testing are highly cost-effective 
relative to status-quo ($21 000, $26 000, and $27 500/QALY) and significantly reduce 
new infections. This is imputable to the preventive benefits of PrEP and early 
knowledge of infection status via testing, and the survival gains from early ART 
initiation. Thirteen strategies consisting of more aggressive test-and-treat and 
PrEP approaches trace the efficient frontier for decision making. More aggres-
sive strategies are more costly but yield better effectiveness profiles, albeit with 
diminishing returns. These results remain generally robust to uncertainty in the 
epidemic, cost, and effectiveness parameters. The relative effectiveness of PrEP is 
however sensitive to PrEP and ART adherence and initiation rates. CONCLUSIONS: 
PrEP and test-and-treat strategies are cost-effective alternatives to the status-quo 
for HIV prevention among LAC MSM. When affordable, aggressive combinations 
of these strategies should be implemented. The effectiveness of these strategies 
could be enhanced with greater adherence to ART and PrEP.
